![The F-35’s future: The power and cooling competition that could change everything [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/09/240924_F35_moon_USAF-scaled-e1727200160419.jpg?#)
GSK revs up launch plans after Nucala's FDA approval in COPD, targeting £500M opportunity
While GSK’s Nucala may not have earned the distinction of becoming the first FDA approved biologic for COPD, the British drugmaker is confident its IL-5 antibody still has a major role to play in tackling the traditionally tough-to-treat respiratory condition. And, now, the company has a fresh FDA green light to put its thesis to the test.
While GSK’s Nucala may not have earned the distinction of becoming the first FDA approved biologic for COPD, the British drugmaker is confident its IL-5 antibody still has a major role to play in tackling the traditionally tough-to-treat respiratory condition. And, now, the company has a fresh FDA green light to put its thesis to the test.
